BioPharma Resources

Drug Trial Radar · NCT02389322

Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65

Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65,Adopting Randomized Blinded and Parallel Controlled Method

Last checked: Nov 19, 2026Latest source record: Mar 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,044 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,044

Actual

Start

Mar 2015

Primary completion

Jul 2015

Study completion Sep 2015

Sponsor

Sponsor type
Industry
Collaborators
Air Force Military Medical University, China; Proswell Medical Corporation; Jiangsu Province Centers for Disease Control and Prevention; Jurong Province Centers for Disease Control and Prevention
First posted
Mar 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The investigators select 500 subjects who meet the standard and are considered as study population I. Do specific gamma-interferon detection before the skin test, then inject intradermally with two dosage ESAT6-CFP10 and Tuberculin purified protein derivative (TB-PPD) at different arm of the same subject and get 192 participants whose three kinds of detection result are all negative and are considered as study population II.Then,they are immune to the Bacillus Calmette-Guerin (BCG) vaccine or the placebo of the BCG. Do specific gamma-interferon detection before the skin test, then inject intradermally with two dosage ESAT6-CFP10 and TB-PPD at different arm of the same subject 12 weeks after immunity.Negative rate of ESAT6-CFP10 after vaccination BCG as the main index , evaluate the specificity of different doses of ESAT6-CFP10, and conform the optimal dose of ESAT6-CFP10.

Conditions

  • Tuberculosis

Interventions

  • 5μg/ml ESAT6-CFP10Biological

    The participants are injection intradermally with 0.1 ml 5μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 5μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .

  • 10μg/ml ESAT6-CFP10Biological

    The participants are injection intradermally with 0.1 ml 10μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 10μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .

  • BCGBiological

    The participants are injected intradermally with 0.1 ml BCG.This BCG is Freeze-dried agent and with five people dose of each bottle,so each bottle of BCG must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .

  • placeboBiological

    The participants are injected intradermally with 0.1 ml placebo of Bacillus Calmette-Guerin.This placebo is Freeze-dried agent and with five people dose of each bottle ,so each bottle must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. immune response of ESAT6-CFP10 from the size of induration or redness in all populationTime frame: within 72 Hours After Intradermal Injection With ESAT6-CFP10
  2. immune response of TB-PPD from the size of induration or redness in all populationTime frame: within 72 Hours After Intradermal Injection With TB-PPD
  3. the results of specificity γ-IFN test in all subjectsTime frame: before administered intradermally

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jurong Province Centers for Disease Control and Prevention

    Jurong, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.